As reported by pharmaphorum last month, Novartis’ Arzerra, a repurposed cancer drug formerly owned by GlaxoSmithKline, outperformed Aubagio in a phase 3 trial last month. Celgene’s ozanimod is ...

While Sanofi's list price of Aubagio is set at £13,529 ($22,100) per patient a year, NICE was able to recommend it for the NHS after Sanofi made the drug available at a discount under the patient ...

Sanofi faces its share of headwinds like generic erosion of key drug Aubagio in all key markets and lower sales from mature products, which are hurting sales. Other headwinds include the weak ...